Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Common Stock Shares Issued

Common Stock Shares Issued at other companies

Incyte logo
IncyteINCY
201M+3.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
60.9M+7.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
18.3M+3.4%
TTR
Turn Therapeutics Inc.TTRX
$29.79M
PTH
Pelthos TherapeuticsPTHS
3.4M
Arcus Biosciences logo
Arcus BiosciencesRCUS
127M+19.4%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.26B+91.5%
Enterprise value$3.34B+92.0%
P/S+0.6×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemJune 30, 2026December 31, 2025
Total liabilities267,958243,494
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1212
Additional paid-in capital1,355,5931,327,595
Accumulated other comprehensive income (loss)(656)(44)
Accumulated deficit(1,134,370)(1,138,084)
Total stockholders’ equity220,579189,479

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s common stock shares issued?
Arcutis Biotherapeutics, Inc. (ARQT) reported common stock shares issued of 125.6M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s common stock shares issued changed year-over-year?
Arcutis Biotherapeutics, Inc.'s common stock shares issued increased by 4.8% year-over-year, from 119.8M to 125.6M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s common stock shares issued?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s common stock shares issued has grown at a 23.1% compound annual growth rate (CAGR), from 43.7M to 123.3M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Arcutis Biotherapeutics, Inc.'s common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude